Nawfal W Istfan1, Wendy A Anderson2, Donald T Hess2, Liqun Yu1, Brian Carmine2, Caroline M Apovian1. 1. Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Department of Medicine, School of Medicine, Boston University/Boston Medical Center, Boston, Massachusetts, USA. 2. Section of Minimally Invasive Surgery, Department of Surgery, School of Medicine, Boston University /Boston Medical Center, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: Weight regain (WR) after Roux-en-Y gastric bypass surgery (RYGB) starts to occur 2 years after surgery, ultimately affecting at least 25% of patients. A limited number of studies have evaluated the impact of antiobesity medications (AOMs) on this phenomenon. METHODS: This study reviewed the electronic medical records of 1,196 patients who underwent RYGB between 2004 and 2015. WR was evaluated by comparing each patient's weight during subsequent postoperative office visits to nadir weight (lowest weight after RYGB, n = 760), taking into consideration the interval during which WR occurred. Patients who were prescribed AOMs and came to follow-up visits were classified as adherent users, whereas those who missed their follow-up visits were considered nonadherent. This study used a linear mixed model, Cox regression, and generalized equation estimator to determine the impact of AOMs on WR trajectory, hazard ratio for time to event, and odds ratio for repeated event occurrence, respectively. RESULTS: Despite the lack of a unified protocol for using AOMs, the three statistical models converged to show that phentermine and topiramate, used individually or in combination, can significantly reduce WR after RYGB. CONCLUSIONS: Phentermine and topiramate are effective in mitigating WR after RYGB. Further studies are needed to help ascertain optimal use of AOMs after bariatric surgery.
OBJECTIVE: Weight regain (WR) after Roux-en-Y gastric bypass surgery (RYGB) starts to occur 2 years after surgery, ultimately affecting at least 25% of patients. A limited number of studies have evaluated the impact of antiobesity medications (AOMs) on this phenomenon. METHODS: This study reviewed the electronic medical records of 1,196 patients who underwent RYGB between 2004 and 2015. WR was evaluated by comparing each patient's weight during subsequent postoperative office visits to nadir weight (lowest weight after RYGB, n = 760), taking into consideration the interval during which WR occurred. Patients who were prescribed AOMs and came to follow-up visits were classified as adherent users, whereas those who missed their follow-up visits were considered nonadherent. This study used a linear mixed model, Cox regression, and generalized equation estimator to determine the impact of AOMs on WR trajectory, hazard ratio for time to event, and odds ratio for repeated event occurrence, respectively. RESULTS: Despite the lack of a unified protocol for using AOMs, the three statistical models converged to show that phentermine and topiramate, used individually or in combination, can significantly reduce WR after RYGB. CONCLUSIONS:Phentermine and topiramate are effective in mitigating WR after RYGB. Further studies are needed to help ascertain optimal use of AOMs after bariatric surgery.
Authors: Alexander Dimitri Miras; Belén Pérez-Pevida; Madhawi Aldhwayan; Anna Kamocka; Emma Rose McGlone; Werd Al-Najim; Harvinder Chahal; Rachel L Batterham; Barbara McGowan; Omar Khan; Veronica Greener; Ahmed R Ahmed; Aviva Petrie; Samantha Scholtz; Stephen R Bloom; Tricia M Tan Journal: Lancet Diabetes Endocrinol Date: 2019-06-04 Impact factor: 32.069
Authors: Mohamed Suliman; Adam Buckley; Alia Al Tikriti; Tricia Tan; Carel W le Roux; Nader Lessan; Maha Barakat Journal: Diabetes Obes Metab Date: 2019-03-25 Impact factor: 6.577
Authors: Kajsa Sjöholm; Pia Pajunen; Peter Jacobson; Kristjan Karason; C David Sjöström; Jarl Torgerson; Lena M S Carlsson; Lars Sjöström; Markku Peltonen Journal: Diabetologia Date: 2015-04-30 Impact factor: 10.122
Authors: Nawfal W Istfan; Marine Lipartia; Wendy A Anderson; Donald T Hess; Caroline M Apovian Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: Fabrizio Muratori; F Vignati; G Di Sacco; L Gavazzi; D Pellegrino; M Del Prete Journal: Eat Weight Disord Date: 2022-06-28 Impact factor: 3.008